Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Shire

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.

Shire

Servier agrees to buy Symphogen to swell its cancer pipeline

Servier agrees to buy Symphogen to swell its cancer pipeline

Symphogen signed a licensing deal with Baxter spin-off Baxalta in 2016 – focusing on cancer – shortly before its $32bn merger with Shire. ... Servier acquired Shire’s oncology business two years later in a deal valued at $2.4bn, thereby inheriting

Pharma funding and M&A in 2020

Pharma funding and M&A in 2020 All this in the same year that Japan’s Takeda acquired Shire, making the combined entity one of the top ten pharmaceutical firms by revenue (and only the second non- American

After FDA refusal, Takeda builds case for subcutaneous Entyvio

After FDA refusal, Takeda builds case for subcutaneous Entyvio Patent expiries and a weak near-term pipeline were the main drivers for Takeda's  $63bn takeover of Shire, which completed in January 2019.

New hires at bluebird bio, BioNTech and Provention Bio

New hires at bluebird bio, BioNTech and Provention Bio Prior to Celgene, she served in a number of roles at Shire, including as group vice president, investor relations.

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda’s subcutaneous Entyvio formulation faces FDA rejection Takeda is also betting on pipeline products from its £46bn takeover of Irish biotech Shire to offset loss from patent challenges, although home-grown products like Entyvio are important too as

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics